Research Papers: Immunology:

Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Hong Ren _, Li Lin, Pingyan Shen, Xiao Li, Jingyuan Xie, Xiaoxia Pan, Wen Zhang and Nan Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:93438-93443. https://doi.org/10.18632/oncotarget.21833

Metrics: PDF 2021 views  |   HTML 3210 views  |   ?  


Hong Ren1, Li Lin1, Pingyan Shen1, Xiao Li1, Jingyuan Xie1, Xiaoxia Pan1, Wen Zhang1 and Nan Chen1

1 Department of Nephrology, Institute of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Correspondence to:

Nan Chen, email:

Keywords: rituximab; steroid-dependent; refractory FSGS; refractory MCD; clinical study, Immunology and Microbiology Section; Immune response; Immunity

Received: September 02, 2016 Accepted: September 05, 2017 Published: October 15, 2017


Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have described our experience treating 6 FSGS and 9 MCD patients with steroid-dependent/refractory nephrotic syndrome (NS) with RTX. Patients received RTX (375 mg/m2) intravenously on days 1, 8, 23, and 29. During a median follow-up of 8 months (range, 3-36 months) after RTX administration, all patients achieved complete or partial remission. Relapses decreased by approximately 30-fold compared with the year preceding RTX treatment, and an 89.27% reduction in proteinuria was observed. Furthermore, RTX treatment could decrease medical costs by 76.52% compared with the costs associated with the long-term use (for 12-13 months) of steroids and immunosuppressive drugs.

In conclusion, RTX treatment was safe and effective for patients with refractory FSGS or MCD.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21833